Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Kymera Therapeutics, Inc.
KYMR
$111.95
Name : Kymera Therapeutics, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $9,208,736,768.00
EPSttm : -3.25
finviz dynamic chart for KYMR
Kymera Therapeutics, Inc.
$111.95
3.33%
$3.86
KYMR — Price & Float Short
—— Fair value ★ EPS beat ★ EPS miss —— Target Price
Float Short %

Float Short %

14.12

Margin Of Safety %

Put/Call OI Ratio

0.68

EPS Next Q Diff

-0.64

EPS Last/This Y

-0.12

EPS This/Next Y

-1.16

Price

112.01

Target Price

138.64

Analyst Recom

1.22

Performance Q

3.54

Upside

-137.6%

Beta

1.98

Ticker: KYMR




19 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-08-28KYMR118.170.697.1310004
2026-08-31KYMR118.940.690.2410054
2026-09-02KYMR118.720.700.7010098
2026-09-03KYMR117.290.700.0010167
2026-09-04KYMR117.360.702.5610201
2026-09-08KYMR116.410.700.3510225
2026-09-09KYMR115.410.7042.0010265
2026-09-10KYMR117.090.700.1210300
2026-09-11KYMR115.050.690.3710473
2026-09-14KYMR114.630.690.1310480
2026-09-15KYMR111.570.690.6510487
2026-09-16KYMR116.470.690.0310529
2026-09-17KYMR118.530.680.2510768
2026-09-18KYMR117.80.680.0410779
2026-09-21KYMR117.730.6713.1510486
2026-09-22KYMR121.990.670.2110551
2026-09-23KYMR115.420.670.4210621
2026-09-24KYMR115.830.673.2410668
2026-09-25KYMR112.060.683.1410805
DateSymbolLatestP/C OIP/C VolTotal OI
19 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-08-28KYMR118.23-31.6- -3.80
2026-08-31KYMR118.86-31.6- -3.80
2026-09-01KYMR119.05-31.1- -3.78
2026-09-02KYMR118.62-31.3- -3.78
2026-09-03KYMR117.76-31.3- -3.78
2026-09-04KYMR117.49-31.3- -3.78
2026-09-08KYMR116.45-31.3- -3.78
2026-09-09KYMR115.36-33.0- -3.81
2026-09-10KYMR117.06-33.0- -3.81
2026-09-11KYMR114.95-33.0- -3.81
2026-09-14KYMR114.65-33.0- -3.81
2026-09-15KYMR113.14-33.0- -3.81
2026-09-16KYMR113.14-33.0- -3.81
2026-09-17KYMR118.50-33.0- -3.81
2026-09-18KYMR117.79-33.0- -3.81
2026-09-21KYMR117.66-33.0- -3.81
2026-09-22KYMR122.01-33.0- -3.81
2026-09-23KYMR115.41-33.0- -3.81
2026-09-24KYMR115.82-33.0- -3.81
2026-09-25KYMR112.01-33.0- -3.81
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




19 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-08-28KYMR-31.77-6.3913.91
2026-08-31KYMR-31.77-6.3913.91
2026-09-01KYMR-31.77-6.3913.91
2026-09-02KYMR-31.77-6.3913.91
2026-09-03KYMR-31.77-6.3913.91
2026-09-04KYMR-31.77-6.3913.91
2026-09-08KYMR-31.20-6.3513.91
2026-09-09KYMR-31.20-6.3513.91
2026-09-10KYMR-31.20-6.3513.91
2026-09-11KYMR-31.19-6.3513.90
2026-09-14KYMR-30.930.7613.90
2026-09-15KYMR-30.930.7613.90
2026-09-16KYMR-30.930.7613.90
2026-09-17KYMR-30.930.7613.90
2026-09-18KYMR-30.930.7613.90
2026-09-21KYMR-30.910.8913.90
2026-09-23KYMR-30.910.8913.90
2026-09-24KYMR-30.910.8913.90
2026-09-25KYMR-30.910.8914.12
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
19 items Current Page1 of 1

Last Quarter Act. EPS​

-0.62

Avg. EPS Est. Current Quarter

-1.25

Avg. EPS Est. Next Quarter

-1.26

Insider Transactions

-30.91

Institutional Transactions

0.89

Beta

1.98

Average Sales Estimate Current Quarter

3

Average Sales Estimate Next Quarter

3

Fair Value

Quality Score

31

Growth Score

34

Sentiment Score

14

Actual DrawDown %

13.9

Max Drawdown 5-Year %

-83.3

Target Price

138.64

P/E

Forward P/E

PEG

P/S

88.65

P/B

6.14

P/Free Cash Flow

EPS

-3.24

Average EPS Est. Cur. Y​

-3.81

EPS Next Y. (Est.)

-4.97

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-285.34

Relative Volume

0.85

Return on Equity vs Sector %

-46.1

Return on Equity vs Industry %

-26.5

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.02

EBIT Estimation

◆ KYMR Healthcare
$111.95
📉
Swing / Pullback
Buy the dip on strong trends
N/A
0 /100
WEAK
Trend
6/20
Pullback
16/25
Volume
7/15
Valuation
7/20
TP/AR
4/10
Options
6/10
RSI
42.5
Range 1M
11.8%
🚀
Momentum Growth
Ride accelerating trends
N/A
27 /100
WEAK
Momentum
5/25
Growth
12/30
Estimates
2/20
Inst/Vol
5/15
Options
3/10
EPS Yr
-4.2%
EPS NY
-32.8%
52W%
76.8%
💎
Long-Term Value
Quality companies, undervalued
N/A
0 /100
WEAK
🟡 HOLD +23.8% upside
Quality
6/30
Valuation
6/30
Growth
7/25
Stability
8/10
LT Trend
0/5
Upside
+23.8%
Quality
31
KYMR — P/E HistoricalBiotechnology
Kymera Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 273
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
KYMR

Latest News

—
Caricamento notizie per KYMR…
stock quote shares  KYMR – Kymera Therapeutics, Inc. Stock Price stock today
news today  KYMR – Kymera Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch  KYMR – Kymera Therapeutics, Inc. yahoo finance google finance
stock history  KYMR – Kymera Therapeutics, Inc. invest stock market
stock prices KYMR premarket after hours
ticker KYMR fair value insiders trading